“We are making incredible strides as we prepare for the potential FDA approval of oxylanthanum carbonate so we can bring this treatment to people with chronic kidney disease on dialysis as efficiently as possible,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “The need for our differentiated treatment, which offers high potency and a significantly reduced pill burden for people struggling to control hyperphosphatemia, has been further validated by new patient survey findings and patient-reported outcomes data. We remain dedicated to bolstering our commercial infrastructure as we strive to deliver a much-needed solution to patients and healthcare providers.”
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Unicycive Therapeutics initiated with a Buy at Guggenheim
- Buy Rating for Unicycive Therapeutics: Competitive Advantages of Oxylanthanum Carbonate in Hyperphosphatemia Treatment
- Unicycive Therapeutics: Buy Rating on Imminent FDA Approval and Market Potential of Oxylanthanum Carbonate
- Unicycive presents new patient-level data from Phase 2 study of OLC
- Buy Rating for Unicycive Therapeutics Amid Favorable Risk/Reward and Strategic Growth Opportunities